Colorado SB26-066: A State-Level Crackdown on Compounded Weight-Loss Medications
Colorado just introduced a bill that squarely targets one category of compounding: weight-loss medications, especially those built from GLP-1–type ingredients.
The bill — Senate Bill 26-066 — is titled:
If you’ve been watching Indiana’s SB 282 debate, Colorado’s proposal will feel familiar — but this one is narrower and more aggressive in specific ways.
Below is a deep, structured breakdown of:
what the bill actually requires
how it compares to existing federal compounding law
where it goes further than federal law
and what it could mean for patient access in Colorado
Full Bill —>
The Framing: Colorado’s Legislative Declaration
The bill’s opening declaration sets the tone.
Colorado lawmakers state that:
FDA approval provides internationally recognized standards.
There are “increasing attempts to circumvent” FDA approval through non-approved compounded medications.
Compounded weight-loss drugs (including compounded GLP-1s) present elevated risks.
High demand has led to proliferation of “illicit, substandard” ingredients.
Some actors are “mass compounding under the guise of personalization.”
2026a_066_introduced
That last phrase matters. It signals that the bill is not just about safety — it’s about scale and commercial behavior.
This is not written as a neutral compliance update. It is written as a corrective response to perceived abuse.
What SB26-066 Actually Regulates
Unlike Indiana’s broader compounding bill, Colorado’s bill applies specifically to “compounded weight-loss medications.”
Definition:
A compounded weight-loss medication is:
created by combining/mixing/altering other drugs or bulk substances, and
intended for use by humans for weight loss.
This is a targeted bill.
Not hormone replacement therapy.
Not pediatric liquid conversions.
Not dermatology creams.
This is about weight-loss compounding.
The Core Restrictions: What Must Be Confirmed Before Sale
Under Section 503A (traditional compounding), a person may not sell, transfer, or distribute compounded weight-loss medication unless they confirm several conditions.
Here’s what Colorado would require:
1. Bulk Drug Substance Standards (USP / NF or FDA component pathway)
Bulk drug substances must:
Comply with an applicable USP or National Formulary monograph, OR
Be components of an FDA-approved drug, OR
Be on the FDA bulk drug list under 21 U.S.C. 353a(b)(1)(A)(i)(III).
So far, that aligns generally with federal 503A structure.
But then it tightens.
2. NDA Confirmation Requirement
If relying on the “component of an FDA-approved drug” pathway, the seller must confirm that:
The bulk drug substance was reviewed as part of a New Drug Application approved by the FDA under Section 505.
This is significant.
Federal 503A does not require state-level confirmation that the bulk substance was reviewed as part of an NDA — it requires that the ingredient qualify under federal compounding allowances.
Colorado adds an affirmative confirmation burden.
3. “Human Pharmaceutical-Grade” Requirement
Bulk drug substances must be confirmed as human pharmaceutical-grade products.
As we saw in Indiana, “pharmaceutical grade” can be tricky if not clearly defined in regulation. The bill does not define the term beyond requiring it.
This becomes an interpretive lever.
4. Certificate of Analysis (COA)
The pharmacy must verify that bulk drug substances:
Have a valid certificate of analysis,
Contain information material to safety and effectiveness,
Include identification and purity confirmation.
This aligns with standard compliance expectations — but Colorado codifies it specifically for weight-loss compounding.
5. FDA Registration + Inspection Within 2 Years
This is one of the strictest provisions.
The manufacturer of the bulk drug substance must:
Be registered with the FDA under 21 U.S.C. 360,
Have been inspected within the previous two years,
The inspection must include CGMP compliance relevant to the bulk substance,
And must be classified “Voluntary Action Indicated” (VAI) or “No Action Indicated” (NAI).
That’s not just “FDA registered.”
That’s:
recently inspected
passing classification
and specifically human drug establishment inspection.
This goes beyond baseline federal compounding text and moves into a state-enforced verification regime.
6. Mandatory Quality Control Testing Before Use
The seller must:
Conduct and document quality control testing of bulk drug substance before use,
Confirm identity and content,
Identify and quantify impurities and justify them.
2026a_066_introduced
Again — not foreign to compliance — but now statutorily required and enforceable per dose.
Labeling Requirements: The Warning Language Is Strong
Colorado requires compounded weight-loss medication labels to:
List every active and inactive ingredient
Include quantity
Include country of origin of each ingredient
Then it mandates this statement:
“THIS IS A COMPOUNDED DRUG. COMPOUNDED DRUGS ARE NOT APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION, HAVE NO EVIDENCE OF SAFETY OR EFFICACY, AND HAVE KNOWN AND UNKNOWN POTENTIAL SIDE EFFECTS.”
This language is unusually sweeping.
Federal law does not require compounded drugs to declare they “have no evidence of safety or efficacy.” That is a policy choice in this bill.
This wording could have substantial reputational and clinical impact.
Advertising Restrictions
The bill prohibits:
False or misleading claims
Unsubstantiated claims
Claims lacking disclosure of side effects and FDA status
And requires advertising to:
Disclose FDA non-approval
Disclose risk information
Disclose the entities used to compound the medication
That’s aggressive transparency.
It also exposes compounding weight-loss marketing to deceptive trade practice enforcement.
Recordkeeping + Inspection Authority
Colorado would require:
Record retention for at least 2 years after expiration date
Records must be produced within one business day upon request
The Board may inspect:
pharmacies
domestic suppliers
wholesalers
repackagers
That is a supply-chain-wide inspection power.
Enforcement: Per-Dose Fines
The Board may:
Issue fines up to $1,000 per dose sold in violation
Revoke pharmacy or business licenses
Attorney General may enforce as deceptive trade practice under Colorado Consumer Protection Act
Per-dose fines change risk calculus dramatically.
This is not symbolic.
Does This Match Federal Law — or Go Further?
Colorado tracks federal law in structure:
References 503A
References FDA bulk drug substance pathways
References FDA establishment registration
But it goes further in several ways:
Inspection recency requirement (2-year window)
Federal law requires registration; it does not impose a state-level “must have passed FDA inspection within 2 years” condition for use in compounding.Mandatory NDA confirmation language
This adds a state-level verification step not explicitly required in federal 503A text.Mandatory label statement declaring “no evidence of safety or efficacy”
This is a strong policy position that exceeds federal labeling norms for compounded drugs.Per-dose financial penalties
Federal enforcement does not operate on a state-imposed per-dose fine model like this.Targeting weight-loss compounding specifically
Federal law regulates compounding broadly. Colorado isolates a single therapeutic category.
The Policy Question Beneath the Policy
The bill assumes:
FDA-approved GLP-1s are widely available.
Mass compounding under “personalization” is occurring.
High demand correlates with illicit supply chain risk.
The question Colorado lawmakers are answering is:
Should states impose a heightened compliance regime on compounded weight-loss drugs because of demand-driven risk?
Whether one agrees depends on:
confidence in existing federal enforcement,
interpretation of supply-chain integrity,
and philosophy on state vs federal oversight.
What Happens If This Passes?
Most likely impacts:
Higher compliance costs for 503A pharmacies compounding weight-loss meds
Increased documentation burden across wholesalers and suppliers
Potential exit of smaller compounding pharmacies from weight-loss space
Shift toward large 503B outsourcing facilities
More conservative marketing language statewide
It does not ban compounded weight-loss medications.
But it raises the bar enough that access may narrow.
TIMEFRAME
Colorado SB26-066 already has a scheduled hearing in committee. It is set for:
Thursday, March 5, 2026 at 1:30 PM MST in the Senate Health & Human Services Committee, in the Old Supreme Court chamber.
This appears to be the first formal committee hearing where the bill will be discussed, and is where testimony from stakeholders (health professionals, pharmacies, patient advocates, etc.) would be heard.
As of now the bill is still “Under Consideration” — it has been introduced and assigned to committee, but the Legislature’s official history does not show that it has passed or been voted on yet.
What you can do?
1. Submit Written Testimony Online (Preferred Method)
Colorado’s legislature allows public comment by uploading written testimony directly to the bill’s portal.
Steps:
Visit the bill’s official page:
https://leg.colorado.gov/bills/SB26-066Scroll to the “Testimony” section.
Click “Submit Written Testimony.”
Upload your comments, position, and any supporting documents.
Select whether you are “For,” “Against,” or “Neutral” on the bill.
Written submissions become part of the public legislative record.
2. Submit Written Testimony by Email
Colorado’s legislature also accepts emailed testimony for committee hearings.
Check which committee is hearing the bill (for SB26-066 it’s the Senate Health & Human Services Committee).
Each committee posts a contact email on the hearing notice when the agenda is published.
Tip: Include “SB26-066 Written Testimony” in the subject line.
3. Testify in Person at the Committee Hearing
The first hearing is scheduled for:
Thursday, March 5, 2026 — 1:30 PM MST
Old Supreme Court Chamber — Colorado State Capitol
If you plan to speak:
Sign up early outside the committee room before the hearing begins (often 30–60 minutes prior).
Bring a paper copy of your testimony/vector if you want to hand it to the committee members.
You’ll usually be allotted 1–3 minutes to speak on behalf of your written comments.
Committee staff or sergeants can walk you through the sign–in process on site.
4. Live Remote (if offered)
Some Colorado committees allow remote testimony via the legislature’s virtual meeting platform.
Look for a Join / Testify Online link on the hearing notice once it’s posted.
Remote sign–in generally opens before the hearing starts.
Virtual testimony is treated the same as in–person testimony.
Tips for Strong Testimony
Be concise and specific. Lawmakers appreciate clarity — especially for technical bills.
State your position up front: “I support / oppose SB26-066 because…”
Focus on the policy impact — e.g., access to care, patient safety, pharmacy operations.
Cite examples or data when feasible.
Avoid personal attacks, threats, or misinformation — these submissions are public.
Deadline Notes
Written testimony is accepted up to the time of the hearing unless the committee sets an earlier deadline.
After a hearing, some committees keep the record open for additional written testimony — check the bill page after March 5.
Where to Track the Hearing
Visit the bill page for agendas and documents:
https://leg.colorado.gov/bills/SB26-066Look for:
“Committee Agenda”
“Testimony Submissions”
“Hearing Recording / Minutes”
Source
Colorado Senate Bill 26-066 (introduced version), Seventy-Fifth General Assembly, Second Regular Session.
Let’s hope it gets cut way back after testimony is heard!!